Skip to content
Search

Latest Stories

NPA discusses 'hub and spoke' with competition watchdog

The National Pharmacy Association has held a meeting with senior officials at the Competition and Markets Authority (CMA) to discuss the potential impact of hub and spoke dispensing on community pharmacy.

The Association has persistently calling on the competition watchdog to look into hub and spoke dispensing to ensure fairness.


A public consultation is currently under way on government plans to enable ‘inter-company hub and spoke’, where a pharmacy outsources elements of its dispensing to a third party, since the Medicines and Medical Devices Act became law in 2021 which paved the way for regulations to legalise the model.

The NPA told senior officials at CMA that a fair and competitive market for hubs would be essential to avoid unintended consequences such as price rises and poor service.

It asked the competition watchdog to consider the matter prior to commencement of the policy and also to commit to a post implementation market review.

NPA vice chair, Nick Kaye, who attended the meeting, said: “It is highly likely only a few companies in the market will be able to provide fully comprehensive external hub dispensing services to pharmacies, at least initially. This would put pharmacies in a weak position as customers and might also lead to a rise in medicines prices for the NHS, the taxpayer and the public.

“If pharmacies are truly to benefit from hub and spoke dispensing, there needs to be a dynamic and competitive market in which hubs compete for the custom of pharmacies on the basis of quality service and price.

“Significant capital investment is necessary to set up a hub as well as ongoing costs. This, together with the current restrictive wholesaler distribution arrangements, presents a formidable barrier to market entry.”

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less